Stock Ratings / Health Care / HKPD / options

MEDS (30) COSM (31) ESYN (41) ZSTK (31) ⌘ Pro Terminal →

Cellyan Biotechnology Co. Ltd (Class A) (HKPD) Options Positioning, Max Pain & Unusual Sweeps

$2.19 +0.46% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $2.19

Cellyan Biotechnology Co. Ltd (Class A) (HKPD) carries a Roarable Rating of D (Sell) with 51/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record: Scores of 51/100 (D) historically posted market-perform odds over rolling 90-day windows (-1.3% avg 90D alpha vs SPY) →

ROARABLE D • SELL / AVOID Cap $5.4M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $2.19 (-0.11%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 51/100 (D) historically posted market-perform odds over rolling 90-day windows (-1.3% avg 90D alpha vs SPY • 49.7% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-3.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for HKPD)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (51/100 Composite)

🔍 WHY HKPD SCORES 51/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (25% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (24% of score)

SEC XBRL Trailing 12 Months: 0% FCF Margin ($151.2K FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning7/20 pts (-13 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-13 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C$2.24-1.8% Next Q

Q2 (-2Q)

Grade C$2.20-9.1% Next Q

Q3 (-1Q)

Grade C-$2.00+9.5% Next Q

Current

Grade D$2.19-1.3% Hist 90D α

Trajectory: C (59) → D (51)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a HKPD Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While HKPD currently carries a cautious 51/100 (D) rating due to Whale & Options Positioning (7/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.05) and Max Pain ($2.30) forces dealer call-delta covering toward $30.45.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $HKPD• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “HKPD Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”

YES 51%NO 49%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±12.5%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (HKPD)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for HKPD.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring HKPD)

✓Walkthrough of HKPD's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

HKPD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -82.48%▼ DESCENDING CHANNEL

2026-10-30O $2.12H $2.19L $1.84C $2.19VOL 27.1K

RES: $6.92SUP: $-0.17SMA50: $3.05SMA200: $9.35

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

HKPD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 HKPD Butterfly Map → + Track HKPD →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on HKPD today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for HKPD. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for HKPD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (HKPD)

Health Care Rank #340 of 1016 ⚔️ MEDS vs HKPD Full Matrix →

1. Head-to-Head Health Care Peer Comparison (HKPD vs. MEDS, COSM, ESYN, ZSTK)

Industry: Other Pharmaceuticals (10 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Cellyan Biotechnology Co. Ltd (Class A) (HKPD) ranks #340 by composite RQD confidence (51/100, grade D) and #939 by equity capitalization ($5.4M). Within this direct 5-issuer industry benchmark cohort, HKPD leads on earnings valuation at N/A trailing P/E, while MEDS leads on capital efficiency and profitability with -35.0% ROIC and -27.5% gross margin. HKPD currently leads its immediate peer cohort in composite quantitative strength at 51/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
HKPD ACTIVE Cellyan Biotechnology Co. Ltd (Class A)	D	51/100	—	—	—	+0.46%	$5.4M	Benchmark Subject
MEDS DataMeds AI Inc.	E	30/100	—	-27.5%	-35.0%	-7.73%	$9.8M	/meds-vs-hkpd →
COSM Cosmos Health Inc.	E	31/100	—	12.1%	-35.0%	+11.45%	$27.9M	/cosm-vs-hkpd →
ESYN EnerSyn Global Inc.	D-	41/100	—	53.0%	-35.0%	+3.10%	$54.4M	/esyn-vs-hkpd →
ZSTK ZeroStack Corp.	E	31/100	—	4.6%	-35.0%	-0.34%	$63.9M	/zstk-vs-hkpd →

2. HKPD Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Cellyan Biotechnology Co. Ltd (Class A) (HKPD) operates in Other Pharmaceuticals (Health Care) with an equity capitalization of $5.4M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. HKPD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is HKPD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Cellyan Biotechnology Co. Ltd (Class A) (NASDAQ: HKPD) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 51/100 at a spot price of $2.19 (+0.46% 1D, market cap $5.4M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, HKPD ranks #340 in composite RQD confidence.

How does HKPD compare to MEDS and COSM in the Health Care sector?

Within the Health Care sector (Other Pharmaceuticals), HKPD carries a Roarable D (51/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, MEDS (DataMeds AI Inc.) holds a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $9.8M) and COSM (Cosmos Health Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $27.9M). Among the 5-stock peer group, HKPD leads on earnings multiple (N/A) while MEDS leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for HKPD?

For Cellyan Biotechnology Co. Ltd (Class A) (HKPD), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #340 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is HKPD trading relative to its 50-day, 200-day, and 52-week technical levels?

HKPD last traded at $2.19 (+0.46% on volume of 10,234 shares), positioning the stock -28.20% below its 50-day simple moving average ($3.05) and -76.58% below its 200-day simple moving average ($9.35). Across its 52-week range of $1.62 to $29.00, HKPD sits at the 2.1% percentile with a 14-day RSI of 35.5 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.92 to $2.46).